Chemed Corporation (NYSE:CHE) Receives Average Rating of “Hold” from Brokerages

Shares of Chemed Corporation (NYSE:CHE) have been assigned a consensus rating of “Hold” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $501.50.

A number of equities research analysts have recently commented on CHE shares. Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings raised Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Royal Bank Of Canada lifted their price objective on Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a research report on Monday, April 27th. Wall Street Zen downgraded Chemed from a “buy” rating to a “hold” rating in a research report on Monday, June 8th. Finally, Oppenheimer lowered their price objective on Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a research report on Friday, February 27th.

Insider Transactions at Chemed

In other Chemed news, Director Andrea R. Lindell sold 1,347 shares of the business’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total transaction of $602,553.51. Following the completion of the sale, the director owned 4,578 shares of the company’s stock, valued at approximately $2,047,876.74. The trade was a 22.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $421.13, for a total value of $842,260.00. Following the sale, the chief executive officer directly owned 90,219 shares of the company’s stock, valued at approximately $37,993,927.47. This trade represents a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.33% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Chemed

A number of institutional investors have recently added to or reduced their stakes in the company. Maripau Wealth Management LLC grew its position in Chemed by 5.4% during the first quarter. Maripau Wealth Management LLC now owns 970 shares of the company’s stock valued at $366,000 after acquiring an additional 50 shares during the period. Segall Bryant & Hamill LLC purchased a new stake in Chemed during the first quarter valued at about $2,293,000. Cim LLC grew its position in Chemed by 1.6% during the first quarter. Cim LLC now owns 2,325 shares of the company’s stock valued at $878,000 after acquiring an additional 37 shares during the period. Amundi grew its position in Chemed by 6,982.7% during the first quarter. Amundi now owns 35,555 shares of the company’s stock valued at $13,431,000 after acquiring an additional 35,053 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in Chemed by 9.4% during the first quarter. EverSource Wealth Advisors LLC now owns 406 shares of the company’s stock valued at $153,000 after acquiring an additional 35 shares during the period. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Chemed Price Performance

Shares of NYSE:CHE opened at $419.07 on Wednesday. The company has a market cap of $5.56 billion, a P/E ratio of 22.84, a P/E/G ratio of 1.57 and a beta of 0.54. The company has a quick ratio of 0.83, a current ratio of 0.85 and a debt-to-equity ratio of 0.11. Chemed has a 52 week low of $365.20 and a 52 week high of $562.77. The business has a fifty day simple moving average of $415.27 and a 200-day simple moving average of $424.42.

Chemed (NYSE:CHE) last announced its quarterly earnings data on Thursday, April 23rd. The company reported $5.65 EPS for the quarter, beating analysts’ consensus estimates of $5.30 by $0.35. The business had revenue of $657.51 million during the quarter, compared to the consensus estimate of $659.22 million. Chemed had a return on equity of 27.18% and a net margin of 10.23%.The business’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.63 earnings per share. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Equities research analysts forecast that Chemed will post 22.3 EPS for the current year.

Chemed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Thursday, May 28th. Chemed’s payout ratio is 13.08%.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.